A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy - APG-20

Amryt Pharmaceuticals Designated Activity Company0 个研究点目标入组 65 人开始时间: 2022年9月30日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Amryt Pharmaceuticals Designated Activity Company
入组人数: 65

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

年龄范围: 0 至 65+（—）
性别: All

入选标准

•Age =12 years at Visit 1, Female subjects must be postmenopausal (defined as cessation of menses for at least 1 year), surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), or willing to use a highly effective method of contraception (such methods include combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation: oral/intravaginal; transdermal/progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable; implantable/intrauterine device [IUD]/intrauterine hormone-releasing system [IUS]/bilateral tubal occlusion/vasectomized partner/ sexual abstinence) for the duration of the study (from the time they sign an informed consent/assent form [ICF], until 4 weeks after the last dose of study treatment). Hormonal contraception alone (including oral, injectable, transdermal, and implantable) is not acceptable; an additional barrier method must be used. Intravaginal hormonal contraception or IUS alone are allowed per Investigator’s discretion. Subjects will not be permitted to commence oral contraceptives while taking study treatment during the study., Male subjects must be surgically sterile or willing to use an acceptable method of contraception for the duration of the study (from the time they sign an ICF), until 4 weeks after the last dose of study treatment. An acceptable method of contraception would be a barrier method, such as condoms, restraining from having sex, or a partner using the approved methods of contraception for female subjects as per Inclusion Criteria #10., Subjects who are blood/egg/sperm donors should be willing to halt donations during the study and for 4 weeks following their last dose of study treatment., Subjects who are willing to provide informed consent/assent prior to any study-specific procedures. If a minor, the subject has a parent or legal guardian able to read, understand, and sign the ICF and/or a Child Assent Form (if applicable), communicate with the Investigator, and understand and comply with the protocol requirements. Adolescent subjects must also read and understand the Child Assent Form, Subjects who are willing to follow the dietary restrictions recommended by the Investigator., Diagnosis of FPLD, defined as: • Clinical diagnosis of FPLD based on deficiency of subcutaneous body fat in a partial fashion assessed by physical examination and low skinfold thickness in anterior thigh by caliper measurement (males =10 mm and females =22 mm), plus 1 of the following: o Documented genetic diagnosis of FPLD (mutations in genes known to be associated with lipodystrophy, e.g., LMNA, PPARG, AKT2, or PLIN1). OR o Documented evidence of positive family history (first-degree biological relative) of FPLD (based on genetic or clinical diagnosis) PLUS 1 minor criterion (below). OR o 2 minor criteria (below) in the absence of a genetic diagnosis or family history, plus all the additional criteria (below, following the minor criteria). MINOR Criteria: ? Diabetes mellitus with requirement for high doses of insulin, e.g., requiring =200 U/day, =2 U/kg/day, or currently taking U-500 insulin. ? Presence of acanthosis nigricans on physical examination. ? History of polycystic ovary syndrome (PCOS) or PCOS-like symptoms (hirsutism, oligomenorrhea, and/or polycystic ovaries). ? History of pancreatitis associated with hypertriglyceridemia. ? Evidence of non-alcoholic fat

排除标准

•Previous treatment with metreleptin., Known history of drug or alcohol abuse within 1 year prior to Screening as assessed according to the Investigator’s judgment, Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 calculated by CKD-EPI for subjects =18 years of age and by Bedside Schwartz for subjects <18 years of age., For females only: currently pregnant (confirmed with a positive pregnancy test) or breastfeeding, Any condition where, in the opinion of the Investigator, participation in this study may pose a significant risk to the subject or could render the subject unable to successfully complete the study (e.g., life expectancy <12 months)., Subjects whose antidiabetic/lipid-lowering therapies and/or other concomitant medications that may affect the primary endpoint results (such as appetite suppressing medications) are not stable at Screening and are likely to require a change in dose during the treatment period, Subjects with ongoing or recent (within the last 3 months prior to Screening) episode of acute pancreatitis, Diagnosis of clinically significant hematological abnormalities (including but not limited to clinically significant leukopenia, neutropenia, bone marrow abnormalities, leukemia or lymphoma, or clinically significant pathological lymphadenopathy)., Malignancy that is ongoing/not in remission or that currently requires or has required active treatment within the past 3 years (with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ [e.g., breast carcinoma, cervical cancer in situ] that have undergone potentially curative therapy)., Leptin levels >20.0 ng/mL, Acquired partial lipodystrophy (APL), Radiation induced PL, Subjects diagnosed with Cushing’s syndrome, Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the Screening visit, Subjects with prior severe hypersensitivity reactions to any of the metreleptin product components, Known to have tested positive for human immunodeficiency virus (HIV) or known to be diagnosed with HIV-related LD. Positive HIV test in countries requiring HIV testing., Are immunocompromised or receiving immunomodulatory drugs

研究者

发起方

Amryt Pharmaceuticals Designated Activity Company

相似试验

进行中（未招募）

不适用

EUCTR2007-005959-42-ATBristol Myers Squibb International Corporation485

进行中（未招募）

不适用

EUCTR2007-005959-42-ITBristol Myers Squibb International Corporation485

进行中（未招募）

1 期

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study ToEvaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement.Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, de 12 semanas de duración, para evaluar la eficacia y la seguridad de la terapia con aripiprazol como adyuvante en el tratamiento de la manía en pacientes con trastorno bipolar I tratados con valproato o litio y que precisan mejoría clínica adicionalBipolar I Mania (manic or mixed episode)Mania Bipolar I (episodio maníaco o mixto)MedDRA version: 9.1Level: LLTClassification code 10026749Term: Mania

EUCTR2007-005959-42-ESBristol Myers Squibb International Corporation485

进行中（未招募）

不适用

EUCTR2007-005959-42-PLBristol Myers Squibb International Corporation485

进行中（未招募）

不适用

EUCTR2007-005959-42-GRBristol Myers Squibb International Corporation485